Bio-Rad Laboratories, Inc.

BIO Healthcare Medical Devices

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 19.0%, free cash flow fell 6.06% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

353.70 11.12 −3.05%
Market cap
$9.8B
P/E
42.5×
Fwd P/E
35.4×
Dividend yield
—
F-score
5/9
Altman Z
3.20
Beneish M
−2.29
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
3.11% 2.50% 10.84% (9.50%)

+8 more TTM periods

Piotroski F-Score
5 7 5 5
ROA
2.17% 1.75% 7.62% (6.66%)
ROIC
0.49% 0.55% 0.41% 2.15%
Return on Tangible Assets
8.63% 6.61% 25.94% (23.63%)
Average Days of Receivables
62.28 60.07 65.08 66.32
Free Cash Flow per Share
13.20 13.26 13.74 12.51
Free Cash Flow
353.10 357.40 374.70 336.90
Capital Expenditures
(139.50) (153.00) (157.50) (154.60)
Other line items
Cash ROIC
3.53% 3.72% 3.67% 3.60%
Accounts Receivable Turnover
5.68 6.09 5.66 5.52
Accounts Payable Turnover
8.81 9.20 9.89 9.73
Inventory Turnover
1.58 1.60 1.66 1.54
Average Days of Payables
42.05 38.97 37.87 38.51
Days of Inventory on Hand
228.76 225.60 217.45 234.16
Tax Rate
(0.37) (0.24) (0.24) (0.20)
Research and Development Expense of Revenue
10.29% 0.00% 0.00% 11.14%
Selling, General and Administrative Expense of Revenue
32.91% 32.74% 32.68% 32.35%
Share Based Compensation of Revenue
0.00% 0.00% 4.13% 0.00%
Interest Coverage
1.09 1.17 0.96 4.57
Operating CF/Net income
2.21 3.02 0.70 (0.73)
Depreciation/Fixed assets
0.00 0.00 0.56 0.00
Capex/Depreciation
0.00 0.00 (0.52) 0.00
Revenue per Share
96.81 96.07 94.75 94.99
Operating CF per Share
18.42 18.93 19.52 18.26
Capex per Share
(5.22) (5.68) (5.78) (5.74)
Capex to Sales
0.05 0.06 0.06 0.06

Fold the line items

Columns are period end dates